An article titled “SSRI antidepressants: altered psychomotor development following exposure in utero?” that appeared in the February, 2013 edition of Prescrire International examines additional risks of prenatal exposure to selective serotonin reuptake inhibitor drugs (SSRIs).  To be clear, a number of other studies have linked adverse birth outcomes linked to SSRI exposure

Last summer, a team of researchers from University of British Columbia (Vancouver) led by G.E. Hanley published a study titled “Infant developmental outcomes following prenatal exposure to antidepressants, and maternal depressed mood and positive affect.” in Early Human Development.  This study examined the relationship between poor early childhood development and gestational exposure

Titled “Further findings linking SSRIs during pregnancy and persistent pulmonary hypertension of the newborn: clinical implications.”, this article appearing in the October, 2012 edition of CNS Drugs by M. Galbally et al., identifies persistent pulmonary hypertension of the newborn (PPHN) as a potential consequence of SSRI exposure before birth.

Galbally et al.

In July, 2014, a team of Norwegian researchers led by K.O. Nakken published an article in Tidsskr Nor Laegeforen titled “Antiepileptic drugs and congenital malformations”, evaluating the consequences of prenatal exposure to epilepsy drugs containing sodium valproate, such as Depacon, Depakene, and Depakote (Abbott Laboratories, Inc.).  To-date, dozens of